37 Krause KM, Serio AW, Kane TR, et al. Aminoglycosides: an overview. Cold Spring Harb Perspect Med 2016 6: a027029. 38 Dietze R, Hadad DJ, McGee B, et al. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med 2008 178: 1180–1185. 39 Minato Y, Thiede JM, Kordus SL, et al. Mycobacterium tuberculosis folate metabolism and the mechanistic basis for para-aminosalicylic acid susceptibility and resistance. Antimicrob Agents Chemother 2015 59: 5097– 5106. 40 Hards K, Robson JR, Berney M, et al. Bactericidal mode of action of bedaquiline. J Antimicrob Chemother 2015 70: 2028–2037. 41 Khoshnood S, Taki E, Sadeghifard N, et al. Mechanism of action, resistance, synergism, and clinical implications of delamanid against multidrug-resistant Mycobacterium tuberculosis. Front Microbiol 2021 12: 717045. 42 Gils T, Lynen L, de Jong BC, et al. Pretomanid for tuberculosis: a systematic review. Clin Microbiol Infect 2022: 28: 31–42. 43 Alghamdi WA, Alsultan A, Al-Shaer MH, et al. Cycloserine population pharmacokinetics and pharmacodynamics in patients with tuberculosis. Antimicrob Agents Chemother 2019 63: e00055-19. 44 Gopal M, Padayatchi N, Metcalfe JZ, et al. Systematic review of clofazimine for the treatment of drug-resistant tuberculosis. Int J Tuberc Lung Dis 2013: 17: 1001–1007. 45 Davies Forsman L, Giske CG, Bruchfeld J, et al. Meropenem-clavulanate has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis. Int J Mycobacteriol 2015 4: Suppl 1, 80–81. 46 World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: Treatment – Drug-susceptible tuberculosis treatment. Geneva, World Health Organization, 2022. 47 National Institute for Health and Care Excellence. Tuberculosis: NICE guideline 33. 2016 edition. www.nice.org. uk/guidance/ng33 48 Nahid P, Mase SR, Migliori GB, et al. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med 2019 200: e93–e142. 49 Caminero JA, Scardigli A, van der Werf T, et al. Treatment of drug-susceptible and drug-resistant tuberculosis. In: Migliori GB, Bothamley G, Duarte R, et al. eds. Tuberculosis (ERS Monograph). Sheffield, European Respiratory Society, 2018 pp. 152–178. 50 Gallardo CR, Rigau Comas D, Valderrama Rodríguez A, et al. Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis. Cochrane Database Syst Rev 2016 2016: CD009913. 51 Menzies D, Benedetti A, Paydar A, et al. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med 2009 6: e1000146. 52 Swaminathan S, Narendran G, Venkatesan P, et al. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial. Am J Respir Crit Care Med 2010 181: 743–751. 53 Lienhardt C, Cook SV, Burgos M, et al. Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial. JAMA 2011 305: 1415–1423. 54 Johnson JL, Hadad DJ, Dietze R, et al. Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am J Respir Crit Care Med 2009 180: 558–563. 55 Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011 365: 1471–1481. 56 Gillespie SH, Crook AM, McHugh TD, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 2014 371: 1577–1587. 57 Merle CS, Fielding K, Sow OB, et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med 2014 371: 1588–1598. 58 World Health Organization. WHO operational handbook on tuberculosis. Module 4: Treatment -Drug-resistant tuberculosis treatment. Geneva, World Health Organization, 2020. 59 Treatment Action Group. An Activist’s Guide to Rifapentine for the Treatment of TB Infection. Date last accessed: 12 February 2023 date last updated: April 2020. www.treatmentactiongroup.org/publication/ an-activists-guide-to-rifapentine-for-the-treatment-of-tb-infection/ 60 Günther G, Guglielmetti L, Leu C, et al. Availability and costs of medicines for the treatment of tuberculosis in Europe. Clin Microbiol Infect 2023 29: 77–84. 61 Paton NI, Cousins C, Suresh C, et al. Treatment strategy for rifampin-susceptible tuberculosis. N Engl J Med 2023 388: 873–887. 62 Turkova A, Wills GH, Wobudeya E, et al. Shorter treatment for nonsevere tuberculosis in African and Indian children. N Engl J Med 2022 386: 911–922. 136 https://doi.org/10.1183/2312508X.10024622 ERS MONOGRAPH |THE CHALLENGE OF TB IN THE 21ST CENTURY